Roth Capital Has Positive Outlook for REVB FY2024 Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB) – Investment analysts at Roth Capital raised their FY2024 earnings per share estimates for shares of Revelation Biosciences in a research note issued to investors on Wednesday, December 4th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($5.58) per share for the year, up from their previous forecast of ($6.22). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($7.80) per share. Roth Capital also issued estimates for Revelation Biosciences’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.00) EPS, FY2026 earnings at ($1.01) EPS and FY2027 earnings at ($0.96) EPS.

Revelation Biosciences Price Performance

REVB stock opened at $0.44 on Monday. The company’s 50 day simple moving average is $0.80 and its 200-day simple moving average is $1.26. Revelation Biosciences has a 12 month low of $0.42 and a 12 month high of $25.26. The firm has a market capitalization of $1.89 million, a PE ratio of -0.03 and a beta of 0.15.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.